KYVERNA THERAPEUTICS INC

KYTXNASDAQ

🏆 #3099 by market capEarnings Nov 10US Equity

$630.67▲ $2.84 (+0.45%)

Simulated price

🔔

Track KYTX

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 0.5%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$422M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Good

No chart data available for KYTX.

Trading Snapshot

Day Range: $624.81 – $640.15
52-Week Range: $5.30 – $13.67
Volume: $3.22B
Avg Volume: $2.23B
Shares Outstanding: 60.8M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $73M
Last Q Revenue: $20M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-2.94
Dividend Yield: —
Dilution (1yr): +9.1%

Why Investors Own KYTX

✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
✓Healthy economics — 73% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KYVERNA THERAPEUTICS INC

KYTX

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$170M▲ +19.1% YoY

Free Cash Flow

−$154M▲ +32.0% YoY

Shares Outstanding

47.2M▲ +9.1% YoY

Net Cash

$95M▲ +$7M YoY

StockOtter · stockotter.space

About KYVERNA THERAPEUTICS INC

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

🦦